Publications by authors named "T Monclair"
Article Synopsis
- This study recommends surgery for localized, resectable neuroblastoma without amplification, though the influence of tumor genomics on outcomes is unclear.
- It analyzed over 300 tumor samples from different cohorts, focusing on differences in outcomes based on patients' age and genomic data.
- Findings indicate that younger patients with stage 1 neuroblastoma have excellent survival rates, while older patients with stage 2 tumors face reduced survival linked to specific genomic changes, particularly losses on chromosome 1p and 11q.
Article Synopsis
- The study aimed to assess how the extent of tumor removal by surgeons impacts survival and progression in patients with high-risk neuroblastoma in a specific clinical trial.
- It included over 1,500 patients, highlighting that those who underwent complete macroscopic excision (CME) had significantly better event-free and overall survival rates compared to those with incomplete macroscopic resection (IME).
- The findings suggest that achieving CME not only improves survival rates but also reduces the likelihood of local tumor progression, even after factoring in immunotherapy treatments.
Background: The European multicenter study LNESG1 was designed to evaluate the safety and efficacy of surgical treatment alone in patients with localised neuroblastoma. In a retrospective, observational study we examined the impact of image-defined risk factors (IDRF) on operative complications and survival (EFS and OS).
Procedure: 534 patients with localised, non-MYCN amplified neuroblastoma were recruited between 1995 and 1999.
Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome.
Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed.